Emily R W Davidson1, Tonya N Thomas2, Erika J Lampert3, Marie Fidela R Paraiso2, Cecile A Ferrando2. 1. Center for Urogynecology & Pelvic Reconstructive Surgery, Obstetrics, Gynecology & Women's Health Institute, Cleveland Clinic, 9500 Euclid Avenue/A81, Cleveland, OH, 44195, USA. davidse3@ccf.org. 2. Center for Urogynecology & Pelvic Reconstructive Surgery, Obstetrics, Gynecology & Women's Health Institute, Cleveland Clinic, 9500 Euclid Avenue/A81, Cleveland, OH, 44195, USA. 3. Cleveland Clinic Lerner College of Medicine, Case Western University, Cleveland, OH, 44195, USA.
Abstract
INTRODUCTION AND HYPOTHESIS: Hysterectomy can be performed during sacrocolpopexy, but there are limited studies comparing the effect of route of hysterectomy on adverse events. We hypothesized there would be no difference in adverse events or patient-reported outcomes in women who underwent minimally invasive sacrocolpopexy with either vaginal or supracervical hysterectomy. METHODS: This was a retrospective chart review with a cross-sectional survey component sent to all consenting patients. Patients were identified by procedure code for sacrocolpopexy and hysterectomy from January 2005 to June 2016. RESULTS: Of the 161 subjects meeting the inclusion criteria, 116 underwent supracervical and 45 vaginal hysterectomy. Overall incidence of perioperative adverse events was low. Vaginal hysterectomy cases were faster (276 vs. 324 min, p < 0.001) and had higher rates of postoperative stress incontinence (22 vs. 9%, p = 0.03). Thirty-one (19%) of all subjects had recurrent prolapse; 10 (6%) underwent repeat surgery. Three (1%) subjects had a mesh exposure (no difference between groups), all treated conservatively. Ninety-six (60%) subjects responded to the survey with a median follow-up of 56 (9-134) months. Ninety-one percent (87) of respondents reported being better since surgery, and 91% (87) reported they would choose the surgery again. Twenty-eight percent (27) reported a surgery-related complication including pain, urinary and bowel symptoms; 8% (8) reported evaluation for recurrent prolapse symptoms, all treated conservatively; 4% (4) of respondents reported a mesh exposure. CONCLUSIONS: Incidence of adverse events is low and not different between patients undergoing minimally invasive sacrocolpopexy with concurrent supracervical or vaginal hysterectomy. One in three patients report pelvic floor symptoms postoperatively, but long-term satisfaction is high.
INTRODUCTION AND HYPOTHESIS: Hysterectomy can be performed during sacrocolpopexy, but there are limited studies comparing the effect of route of hysterectomy on adverse events. We hypothesized there would be no difference in adverse events or patient-reported outcomes in women who underwent minimally invasive sacrocolpopexy with either vaginal or supracervical hysterectomy. METHODS: This was a retrospective chart review with a cross-sectional survey component sent to all consenting patients. Patients were identified by procedure code for sacrocolpopexy and hysterectomy from January 2005 to June 2016. RESULTS: Of the 161 subjects meeting the inclusion criteria, 116 underwent supracervical and 45 vaginal hysterectomy. Overall incidence of perioperative adverse events was low. Vaginal hysterectomy cases were faster (276 vs. 324 min, p < 0.001) and had higher rates of postoperative stress incontinence (22 vs. 9%, p = 0.03). Thirty-one (19%) of all subjects had recurrent prolapse; 10 (6%) underwent repeat surgery. Three (1%) subjects had a mesh exposure (no difference between groups), all treated conservatively. Ninety-six (60%) subjects responded to the survey with a median follow-up of 56 (9-134) months. Ninety-one percent (87) of respondents reported being better since surgery, and 91% (87) reported they would choose the surgery again. Twenty-eight percent (27) reported a surgery-related complication including pain, urinary and bowel symptoms; 8% (8) reported evaluation for recurrent prolapse symptoms, all treated conservatively; 4% (4) of respondents reported a mesh exposure. CONCLUSIONS: Incidence of adverse events is low and not different between patients undergoing minimally invasive sacrocolpopexy with concurrent supracervical or vaginal hysterectomy. One in three patients report pelvic floor symptoms postoperatively, but long-term satisfaction is high.
Authors: Blake C Osmundsen; Amanda Clark; Crystal Goldsmith; Kerrie Adams; Mary Anna Denman; Renee Edwards; William Thomas Gregory Journal: Female Pelvic Med Reconstr Surg Date: 2012 Mar-Apr Impact factor: 2.091
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Ingrid Nygaard; Linda Brubaker; Halina M Zyczynski; Geoffrey Cundiff; Holly Richter; Marie Gantz; Paul Fine; Shawn Menefee; Beri Ridgeway; Anthony Visco; Lauren Klein Warren; Min Zhang; Susan Meikle Journal: JAMA Date: 2013-05-15 Impact factor: 56.272
Authors: Cecile A Unger; Marie Fidela R Paraiso; John E Jelovsek; Matthew D Barber; Beri Ridgeway Journal: Am J Obstet Gynecol Date: 2014-08-01 Impact factor: 8.661
Authors: Jasmine Tan-Kim; Shawn A Menefee; Karl M Luber; Charles W Nager; Emily S Lukacz Journal: Int Urogynecol J Date: 2010-09-15 Impact factor: 2.894
Authors: Deepanjana Das; Allison Carroll; Margaret Mueller; Kimberly Kenton; Christina Lewicky-Gaupp; Sarah Collins; Julia Geynisman-Tan; C Emi Bretschneider Journal: Int Urogynecol J Date: 2022-06-06 Impact factor: 1.932
Authors: Katherine L Woodburn; Amr Sherif El Haraki; Andrew I Sokol; Robert E Gutman; Catherine A Matthews Journal: Int Urogynecol J Date: 2022-02-14 Impact factor: 1.932
Authors: Daniel Gagyor; Vladimir Kalis; Martin Smazinka; Zdenek Rusavy; Radovan Pilka; Khaled M Ismail Journal: BMC Womens Health Date: 2021-02-17 Impact factor: 2.809